[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100489430":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":10,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":10,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":10,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":75,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Seoul National University Bundang Hospital","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group",null,"Patients who are not diagnosed with inflammatory bowel disease and have colitis.",[13],"Other: Endoscopic biopsy",{"label":15,"type":10,"description":16,"interventionNames":17},"TNF-alpha Inhibitor-naive IBD group","Patients who are diagnosed with inflammatory bowel disease but do not have a history of TNF-a inhibitor treatment.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"TNF-alpha Inhibitor-treated IBD group","Patients who are diagnosed with inflammatory bowel disease and have a history of TNF-a inhibitor treatment.",[13],[23],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Endoscopic biopsy","When patients have colonoscopy or sigmoidoscopy for evaluation of their disease course, biopsied samples are collected.\n\nIn the IBD group, samples are obtained at endoscopically active and\u002For inactive lesions. In the control group, samples are obtained at endoscopically normal lesions.",[9,15,19],[28],{"name":29,"affiliation":5,"role":30},"Nayoung Kim, M.D., Ph.D","STUDY_CHAIR",[32],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},"Yu kyung Jun, M.D., Ph.D","CONTACT","+ 82-31-787-7845","juk0220@nate.com",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":10,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Seongnam-si","Gyeonggi-do","463-707","South Korea",{"type":45,"coordinates":46},"Point",[47,48],127.13778,37.43861,{"lat":48,"lon":47},[51],{"name":52,"role":53,"phone":10,"phoneExt":10,"email":10},"Nayoung Kim, M.D.,Ph.D.","PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Nayoung Kim","professor","100489430","predictors-of-prognosis-in-ibd-patients-100489430",false,"NCT05653011","Predictors of Prognosis in IBD Patients","Predictors of Response After Induction Therapy With TNF-alpha Inhibitor in Inflammatory Bowel Disease, Comparison to Normal","Inclusion Criteria:\n\n* control group: Patients who do not have colitis, cancer, and advanced polyp (the number of polyps ≥ 3, the size of polyps ≥ 1cm, high-grade adenoma, villous adenoma)\n* TNF-α inhibitor-naive IBD group: IBD patients who do not have a history of TNF-α inhibitor treatment\n* TNF-α inhibitor-treated IBD group: IBD patients who are treated with TNF-α inhibitor\n\nExclusion Criteria:\n\n* Age under 18 years\n* Patients who were treated with antibiotics or probiotics within the last 3 months","ALL","18 Years",{"count":67,"type":68},100,"ESTIMATED","OBSERVATIONAL","A study of clinical characteristics and potential prognostic factors in inflammatory bowel disease",[72,73,74],"Inflammatory Bowel Diseases","Ulcerative Colitis","Crohn Disease",[76,77,78],"inflammatory bowel disease","ulcerative colitis","crohn's disease","2026-04-23",{"date":81,"type":82},"2026-04-24","ACTUAL",{"date":84,"type":82},"2013-03-11",{"date":86,"type":68},"2026-12-31",{"name":5,"class":6},1]